S8600-S9031-S9333-A, Study of DNA in Samples From Patients With Acute Myeloid Leukemia

S8600-S9031-S9333-A, Identification of Differentially Methylated Genomic Regions That Are Prognostically Significant in AML

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01434329

Enrollment

200

Registered

2011-09-14

Start date

2011-10-31

Completion date

2015-12-31

Last updated

2016-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia

Keywords

untreated adult acute myeloid leukemia

Brief summary

RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients respond to treatment. PURPOSE: This research trial studies DNA in samples from patients with acute myeloid leukemia.

Detailed description

OBJECTIVES: * To identify differentially methylated regions (DMRs) associated with overall survival (OS) of acute myeloid leukemia (AML) patients with normal cytogenetics. * To develop and evaluate in an independent validation set a prognostic score for OS based on the identified DMR. * To determine whether the prognostic score can group patients into risk groups based on OS. OUTLINE: Archived blood or bone marrow samples are analyzed for DNA methylation alterations by CHARM array-based genome assay. Each patient's clinical data is also collected.

Interventions

GENETICDNA methylation analysis

GENETICgene expression analysis

GENETICmicroarray analysis

OTHERlaboratory biomarker analysis

OTHERmedical chart review

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * De novo acute myeloid leukemia (AML) patients with normal cytogenetics treated with curative therapy who survived at least 28 days after therapy started * Samples will be taken from the following studies: SWOG-8600, SWOG-9031, SWOG-9333, SWOG-9500, SWOG-S9918, SWOG-S0106, and SWOG-S0112 * Blood or marrow specimens can be used PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

Measure	Time frame
Identification of DMRs associated with OS	immediate
Development and evaluation of a prognostic score of OS based on DMRs identified	immediate
Prognostic score able to group AML patients into risk groups	immediate

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026